Overview

Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Status:
Terminated
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in treating subjects with type 2 diabetes mellitus.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda